Kiniksa Pharmaceuticals International, plc research snapshot
KNSA AI stock analysis currently reads Kiniksa Pharmaceuticals International as a high-growth commercial-stage biopharmaceutical company whose ARCALYST franchise delivered a second-quarter beat-and-raise, with raised 2026 guidance, a debt-free balance sheet, and a pivotal Phase 3 trial for the KPL-387 pipeline asset now enrolling patients. The analysis is not a certain price prediction. At the August 3, 2026 data cutoff, the latest verified close was $74.34 on July 31, 2026, market capitalization was about $5.80 billion, and the stock was up about 147% over the prior 52 weeks. The main question was whether Kiniksa can sustain roughly 35% to 55% ARCALYST revenue growth, convert the KPL-387 Phase 3 into a second commercial product in the 2028 to 2029 timeframe, and justify a trailing earnings multiple near 75x. This is informational research and not investment advice.
Current price
$74.34
Market cap
$5.80 billion
AI score
68 / 100
Rating
Strong commercial growth and raised guidance, offset by a high multiple and single-product dependence
Trend status
Strong uptrend above the 50-day and 200-day moving averages, near the 52-week high
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Kiniksa commercializes ARCALYST, the only FDA-approved treatment for recurrent pericarditis, with roughly three-year average therapy duration, a growing prescriber base above 5,000, profitable operations, and a debt-free balance sheet. | High |
| Moat | ARCALYST benefits from orphan drug exclusivity, first-mover brand position, physician habit, and limited approved alternatives, but the IL-1 pathway is contested by anakinra and emerging IL-1 directed candidates, so the moat is regulatory and commercial rather than structural. | Medium |
| Management | Chairman and CEO Sanj Patel has a strong biopharma track record including Synageva through its Alexion sale, and Q2 2026 execution was disciplined with cash generation, but the board retains a concentrated-ownership history and governance should be monitored. | Medium |
| Financial trend | Q2 2026 revenue rose about 55% year over year to $243.6 million, H1 2026 revenue reached $457.9 million with $48.0 million of net income, and the company raised FY2026 ARCALYST guidance to $980 million to $995 million from $930 million to $945 million. | High |
| Valuation | At $74.34, KNSA traded near 75x trailing earnings, 52x forward earnings, 6.9x sales, 8.9x book value, and 31.7x free cash flow, a premium that reflects rapid growth but leaves little room for execution misses. | Medium |
| Technical trend | KNSA closed at $74.34 on July 31, 2026, well above its 50-day moving average near $58.80 and 200-day moving average near $47.98, with RSI around 64 and a 52-week high of $82.94, supporting a strong near-term uptrend. | Medium-high |
| Risk level | Key risks are dependence on a single product, high valuation, gross-to-net pressure, potential IL-1 pathway competition, Phase 3 timing for KPL-387, short interest near 10.2% of float, and biotech sector volatility. | Medium-high |
| AI confidence | High confidence for reported financials, market cap, analyst consensus, and technical snapshot. Lower confidence for long-term pipeline valuation and durable multiple support. | High data confidence |
| Investment certainty | Medium-low certainty. The commercial momentum and balance sheet are real, but the high price and single-product dependence require strong conviction that growth and the premium multiple can be sustained. | Medium-low |
KNSA AI stock forecast
The KNSA AI stock forecast uses scenario ranges around the $74.34 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained roughly 35% to 45% ARCALYST growth, smooth KPL-387 Phase 3 progress, and maintenance of a premium forward multiple. The base case assumes guidance is executed and growth moderates toward 30%. The bearish case assumes growth deceleration, gross-to-net or competitive pressure, pipeline slippage, or multiple compression.
$95 to $115
More likely if ARCALYST sustains 35% to 45% annual revenue growth, PASTORALE Phase 3 enrollment advances on schedule, KPL-1161 enters Phase 1 by the end of 2026, gross-to-net stays favorable, and the market keeps KNSA near or above 65x forward earnings, consistent with the $100 to $108 analyst targets from Citi and J.P. Morgan.
$78 to $90
More likely if FY2026 guidance of $980 million to $995 million is executed, ARCALYST grows around 30% annually, the KPL-387 program advances without major delays, and KNSA holds a forward multiple near 55x to 65x, a range supported by the consensus price target of $98.
$50 to $65
More likely if ARCALYST growth decelerates from gross-to-net pressure or IL-1 pathway competition, PASTORALE enrollment or data slip, KPL-1161 development stalls, or the market compresses KNSA toward a 40x to 45x forward multiple reflecting single-product biotech risk.
KNSA AI technical analysis
KNSA AI technical analysis starts from the $74.34 July 31, 2026 close used for this August 3 static page. The stock is in a strong uptrend, trading well above its 50-day and 200-day moving averages after a post-earnings breakout. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $74.34 | Latest verified close on July 31, 2026, used for market cap and valuation math at the August 3, 2026 data cutoff. |
| Near support | $70 to $71 | The round-number zone below the post-earnings gap that formed after the July 28 beat-and-raise quarter. |
| Secondary support | $63 to $65 | The pre-earnings breakout area. A sustained break below this zone would weaken the post-earnings uptrend. |
| 50-day moving average | About $58.80 | Price is well above this intermediate trend gauge, supporting the positive short-term trend. |
| 200-day moving average | About $47.98 | The long-term trend reference. Price is far above it, so a break back below would signal a major trend failure. |
| Near resistance | $78 to $80 | The post-earnings high zone near $78.69 and the prior close near $78.20. A move above it with volume would confirm continued momentum. |
| High resistance | About $82.94 | The 52-week high is the next reference point if KNSA clears the $78 to $80 band. |
| Momentum | RSI about 64.24 | Momentum is strong but not yet overbought, leaving room for continued upside if volume confirms. |
| Volume | About 794,000 average daily shares, 1.03 million on July 31 | Breakouts above resistance should be judged against average volume because low-volume moves can fade. |
| Volatility | Reported beta 0.07, high single-stock event risk | The reported stock beta looks low for a commercial biotech, so position sizing should instead account for binary earnings and clinical-data risk. |
| Invalidation | Close below $70, then $63 | A close below the $70 to $71 support weakens the near-term setup. A break below $63 would challenge the post-earnings trend and open the $58 to $60 area. |
KNSA AI trading strategy
The KNSA AI trading strategy is a rules-based framework, not personalized advice. It combines commercial execution evidence, clinical milestone tracking, technical confirmation, position sizing, and clear invalidation levels.
Look for KNSA to hold above the $70 to $71 support zone while ARCALYST revenue and guidance trends stay positive. Enter on pullbacks toward support with improving volume confirmation and no adverse pipeline or pricing news.
A daily close below $70 or a negative revision to FY2026 guidance should reduce confidence in the trend-following setup.
If KNSA pulls back from the $78 to $80 resistance zone without a thesis break, assess whether the sell-off reflects profit-taking after the July beat-and-raise or fundamental deterioration in growth or gross-to-net.
Do not average down solely because of the growth narrative. Define a maximum loss before entering and respect the $70 invalidation level.
Track quarterly ARCALYST revenue growth, gross-to-net trends, collaboration profit, prescriber growth, PASTORALE Phase 3 enrollment and data timing, KPL-1161 Phase 1 timing, analyst target revisions, and short interest changes.
Lower the rating if revenue growth decelerates, gross-to-net erodes, Phase 3 timelines slip, insider selling intensifies, or the forward multiple compresses without a compensating growth upgrade.
Investment research summary
Kiniksa discovers and commercializes therapies for inflammatory diseases with unmet need, focused on cardiovascular indications. ARCALYST for recurrent pericarditis is the sole revenue driver, with KPL-387 and KPL-1161 targeting adjacent IL-1 pathway opportunities.
ARCALYST holds orphan drug exclusivity and is the only FDA-approved therapy for recurrent pericarditis, with more than 5,000 prescribers and an average therapy duration of about three years. The moat is real but depends on label position, payer coverage, and the absence of competitive IL-1 entrants.
The thesis fails if ARCALYST growth decelerates from gross-to-net pressure, payer changes, or IL-1 pathway competition, if PASTORALE Phase 3 enrollment or results disappoint, if KPL-1161 stalls, or if a trailing multiple near 75x contracts as growth normalizes.
Chairman and CEO Sanj Patel has a strong biopharma track record including Synageva through its sale to Alexion. The executive team has deep commercial and clinical experience, and Q2 2026 showed disciplined capital allocation with about $58 million of net cash generation for the quarter.
Kiniksa operates at the intersection of cardiology and immunology in recurrent pericarditis, where the 2025 ACC concise clinical guidance supports moving IL-1 inhibition earlier in the treatment line. The trend toward targeted biologic therapies favors long-term demand, but the IL-1 space is attracting new entrants.
At roughly 75x trailing earnings and 52x forward earnings, the stock embeds high near-term growth expectations. A margin of safety would require conviction that 30% to 45% revenue growth is sustainable, that PASTORALE executes, and that the premium multiple can be defended against a growing pipeline of alternatives.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| KNSA price | $74.34 close on July 31, 2026 | StockAnalysis (S&P Global) market data snapshot | August 3, 2026 |
| Market capitalization | $5.80 billion, verified as $74.34 x 78.02 million shares with 0.00% variance | financial_rigor.py market cap verification | August 3, 2026 |
| Shares outstanding | 78.02 million shares, up 9.97% year over year, with 4.51% insider ownership and 61.96% institutional ownership | StockAnalysis statistics | August 3, 2026 |
| Q2 2026 revenue and EPS | $243.6 million total revenue (about 55% year-over-year growth), $25.4 million net income, and $0.30 diluted EPS versus consensus of $0.28 | Kiniksa Q2 2026 earnings release, July 28, 2026 | August 3, 2026 |
| H1 2026 revenue and EPS | $457.9 million total revenue, $48.0 million net income, and $0.58 diluted EPS | Kiniksa Q2 2026 earnings release | August 3, 2026 |
| FY2025 financials | $677.56 million revenue and $59.01 million net income, cross-validated across StockAnalysis and company reporting with 0.00% variance | StockAnalysis financials and Kiniksa FY2025 filings | August 3, 2026 |
| FY2026 guidance (raised) | ARCALYST net product revenue of $980 million to $995 million, raised from $930 million to $945 million on July 28, 2026 | Kiniksa Q2 2026 earnings release | August 3, 2026 |
| TTM results | $840.85 million revenue, $80.66 million net income, $0.99 EPS, $100.25 million operating income, and $182.84 million free cash flow | StockAnalysis financials | August 3, 2026 |
| Cash and debt | $525.9 million of cash, cash equivalents, and short-term investments and no debt at June 30, 2026; StockAnalysis reports net cash of $517 million | Kiniksa Q2 2026 earnings release and StockAnalysis balance sheet | August 3, 2026 |
| Valuation ratios | 75.07x TTM PE, 52.26x forward PE, 6.90x PS, 8.86x PB, 31.72x P/FCF, and 51.78x EV/EBITDA based on the July 31 close | StockAnalysis statistics and financial_rigor.py valuation verification | August 3, 2026 |
| Technical snapshot | 50-day moving average $58.80, 200-day moving average $47.98, RSI 64.24, 52-week range $29.90 to $82.94, and 20-day average volume about 794,000 shares | StockAnalysis statistics | August 3, 2026 |
| Analyst consensus | Strong Buy from 8 analysts with an average price target of $98 and a range of $87 to $108, with post-earnings target raises from Citi, J.P. Morgan, Wedbush, Canaccord, and Goldman Sachs | StockAnalysis forecast | August 3, 2026 |
| Short interest | 4.51 million shares short, equal to 5.78% of shares outstanding and 10.21% of float, with 4.34 days to cover | StockAnalysis statistics | August 3, 2026 |
| KPL-387 program | Phase 2 data showed median time to treatment response of 4.0 days at the 300 mg monthly dose, and the pivotal Phase 3 study PASTORALE is enrolling up to about 85 patients with a 2028 to 2029 potential launch timeframe | Kiniksa Q2 2026 earnings release | August 3, 2026 |
| Market penetration | About 21% of the 14,000 multiple-recurrence patient population on ARCALYST therapy at June 30, 2026, up from about 18% at the end of 2025, with more than 5,000 prescribers since launch | Kiniksa Q2 2026 earnings call | August 3, 2026 |
This KNSA AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong. Always verify live market data and company filings before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
